Nanobiotix S.A. ADR (NBTX) News
Filter NBTX News Items
NBTX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
NBTX News Highlights
- NBTX's 30 day story count now stands at 4.
- Over the past 1 day, the trend for NBTX's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- The most mentioned tickers in articles about NBTX are MD and VIEW.
Latest NBTX News From Around the Web
Below are the latest news stories about Nanobiotix SA that investors may wish to consider to help them evaluate NBTX as an investment opportunity.
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share CapitalPARIS, February 10, 2022--Regulatory News: Nanobiotix (Paris:NANO) (NASDAQ:NBTX): |
Why Phibro Shares Are Trading Higher Today?View more earnings on DYAISee more from BenzingaEnsign Group Shares Gain On Mixed Q4 Results, Better-Than-Expected FY22 OutlookNanobiotix's Lead Product Shows Feasibility With No Treatment-Related Toxicity In Pancreatic Cancer Patient© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. |
Nanobiotix's Lead Product Shows Feasibility With No Treatment-Related Toxicity In Pancreatic Cancer PatientNanobiotix (NASDAQ: NBTX) has announced the publication of a peer-reviewed case study in Clinical and Translational Radiation Oncology. The case study reports on the first patient treatment experience with potential first-in-class radioenhancer NBTXR3 in pancreatic ductal adenocarcinoma. Nanobiotix and MD Anderson are collaborating to expand the development of NBTXR3 beyond the Company's priority pathways in locally advanced head and neck squamous cell carcinoma and immunotherapy. This ongoing P |
Nanobiotix Announces Publication of New Clinical Case Study Highlighting First Patient Experience of NBTXR3 Treatment for Pancreatic CancerPARIS & CAMBRIDGE, Mass., February 09, 2022--Regulatory News: NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced the publication of a peer-reviewed case study by researchers at The University of Texas MD Anderson Cancer Center in Clinical and Translational Radiation Oncology. The case study reports on the first patient experience o |
NANOBIOTIX Announces Publication of New Preclinical Immunotherapy Data Showcasing the Combination Potential of NBTXR3 With anti-PD-1 and anti-CTLA-4PARIS & CAMBRIDGE, Mass., January 26, 2022--Regulatory News: NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’) (Paris:NANO) (NASDAQ:NBTX), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced the publication of new preclinical immunotherapy data for novel, potentially solid tumor- and therapeutic combination-agnostic radioenhancer NBTXR3 in the Journal of Nanobiotechnology. |
NANOBIOTIX Provides Corporate Update and Highlights Key 2022 Milestone TargetsPARIS & CAMBRIDGE, Mass., January 10, 2022--Regulatory News: NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today provided a corporate update highlighting key priorities and anticipated development milestones for 2022. |
Eargo, Nanobiotix top healthcare gainers, Aligos, Berkeley Lights among losersNo summary available. |
Nanobiotix Rallies After Enrolling First Patient in Head and Neck Cancer TreatmentBy Sam Boughedda |
Nanobiotix enrolls 1st patient in phase 3 trial of NBTXR3 in head, neck cancerNo summary available. |
NANOBIOTIX Announces First Patient Enrolled in NANORAY-312 Global Phase III Registrational Study of NBTXR3 in Head and Neck CancerPARIS & CAMBRIDGE, Mass., January 05, 2022--Regulatory News: NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX – the "Company"), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that the first patient has been enrolled in NANORAY-312, a global, open-label, two-arm, randomized, Investigator’s Choice phase III registration study that is designed to investigate the efficacy and safety of radiotherapy- |